|[February 19, 2014]
Research and Markets: Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/v8443g/global_rnai_drug)
has announced the addition of the "Global
RNAi Drug Delivery Market 2014-2018" report to their offering.
The analysts forecast the Global RNAi Drug Delivery market to grow at a
CAGR of 21.80 percent over the period 2013-2018. One of the key factors
contributing to this market growth is the increase in RNA therapeutic
development. The Global RNAi Drug Delivery market has also been
witnessing some key technological advancements. However, the targeted
delivery of RNA molecules is expected to pose a challenge to the growth
of this market.
Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis
Pharmaceuticals, Inc., Merck & Co. Inc., and TekmiraPharmaceuticals
Other vendors mentioned in the report are Access Pharmaceuticals Inc.,
Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina
Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi
Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere
Therapeutics Inc., and Traversa Therapeutics Inc.
Commenting on the report, an analyst from the team said: Major advances
in RNAi drug delivery are aimed at developing better delivery agents
with excellent efficacy and the ability to target specific cells. For
example, Bio-Path Holdings Inc. developed systemic delivery of
antisense, small interfering RNA, and hydrophobic small molecules for
treatment of various diseases using its neutral lipid drug delivery
technology (neutral liposome). Similarly, Inovio's skin electroporation
technology was used for the successful delivery of small interfering RNA
molecules to skin in animal studies. Thus, technological innovations
would further contribute to the growth of the Global RNAi Drug Delivery
According to the report, one of the major drivers in this market is the
increase in RNA therapeutic development. Therapeutic benefits greatly
depend on the efficiency of the RNA delivery to specific diseased cells.
This factor is the key to the development of RNAi drug delivery
technologies and the market associated with it.
For more information visit http://www.researchandmarkets.com/research/v8443g/global_rnai_drug
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ InfoTech Spotlight's Homepage ]